Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiac Action Potential01:30

Cardiac Action Potential

Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Orally bioavailable CB<sub>2</sub> receptor agonists attenuate neuroinflammation and stabilize the blood-brain barrier.

Research square·2026
Same author

<i>De novo</i> purine synthesis reprograms the macrophage inflammatory response and the immune response in sepsis.

Research square·2026
Same author

Genetic evidence that FGF21 signaling reduces problematic alcohol use and alcohol-related liver disease.

Journal of hepatology·2026
Same author

Metabolic reprogramming and intracellular ATP homeostasis in immunity.

Pharmacology & therapeutics·2026
Same author

P2X4 receptors on myeloid cells mediate tissue injury in a model of trauma and hemorrhagic shock in male mice.

Purinergic signalling·2026
Same author

P2X4 receptors on myeloid cells mediate tissue injury in a murine model of trauma and hemorrhagic shock.

Research square·2025
Same journal

Loss of ETV4 triggers PPM1E downregulation and AMPK-ULK1-dependent autophagy to promote intrinsic trametinib resistance in breast cancer.

Pharmacological research·2026
Same journal

Editorial: Current pharmacological challenges of Treatment-Resistant Depression.

Pharmacological research·2026
Same journal

GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles.

Pharmacological research·2026
Same journal

Sinomenine regulates the AKT/FOXO3/GLUL pathway to inhibit pulmonary fibroblast-to-myofibroblast transition via α7nAChR against rheumatoid arthritis associated interstitial lung disease.

Pharmacological research·2026
Same journal

Ketohexokinase: A central mediator of fructose-associated pathogenesis and promising therapeutic target.

Pharmacological research·2026
Same journal

GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies.

Pharmacological research·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

Endocannabinoids and cardiac contractile function: pathophysiological implications.

Sándor Bátkai1, Pál Pacher

  • 1Phenotyping Core, Laboratory of Physiological Studies, NIAAA, National Institutes of Health, 5625 Fishers Lane, MSC-9413, Bethesda, MD 20892-9413, USA. sbatkai@mail.nih.gov

Pharmacological Research
|July 2, 2009
PubMed
Summary
This summary is machine-generated.

The endocannabinoid system (ECS) plays a role in cardiovascular diseases. Modulating the ECS, particularly CB1 receptors, shows therapeutic promise for heart conditions like cirrhotic cardiomyopathy and doxorubicin-induced heart failure.

More Related Videos

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

Related Experiment Videos

Last Updated: Jun 22, 2026

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Pharmacology

Background:

  • The endocannabinoid system (ECS) is a bioactive lipid signaling network present in both the central nervous system and peripheral organs.
  • Dysregulation of the ECS is implicated in the development of various cardiovascular diseases, including hypertension, atherosclerosis, and heart failure.
  • While chronic CB1 receptor blockade has risks, ECS modulation offers potential therapeutic benefits for cardiovascular disorders.

Purpose of the Study:

  • To review recent advances in understanding the role of CB1 receptors and endocannabinoids in cardiac function.
  • To explore the ECS's involvement in cirrhotic cardiomyopathy.
  • To examine the ECS's role in doxorubicin-induced heart failure.

Main Methods:

  • Literature review of current research on the endocannabinoid system and cardiovascular function.
  • Analysis of studies investigating CB1 receptor and endocannabinoid involvement in cardiac pathophysiology.
  • Focus on specific conditions: cirrhotic cardiomyopathy and doxorubicin-induced heart failure.

Main Results:

  • The ECS significantly influences cardiac function.
  • Evidence suggests a critical role for CB1 receptors in the pathogenesis of cardiovascular complications in liver cirrhosis.
  • The ECS is involved in the mechanisms underlying doxorubicin-induced cardiotoxicity.

Conclusions:

  • Modulation of the endocannabinoid system, particularly CB1 receptors, presents a promising therapeutic strategy for cardiovascular diseases.
  • Targeting the ECS may offer novel treatment options for conditions such as cirrhotic cardiomyopathy and chemotherapy-induced heart failure.
  • Further research into ECS pathways is warranted for developing effective cardiovascular therapies.